	US 12,454,563 B2
	Immune cell function
Ruth E. Winter, Oakland, CA (US); and Saikat Banerjee, Oakland, CA (US)
Assigned to Kite Pharma, Inc., Santa Monica, CA (US)
Filed by Kite Pharma, Inc., Santa Monica, CA (US)
Filed on Mar. 9, 2022, as Appl. No. 17/690,968.
Claims priority of provisional application 63/210,300, filed on Jun. 14, 2021.
Claims priority of provisional application 63/159,610, filed on Mar. 11, 2021.
Prior Publication US 2022/0289815 A1, Sep. 15, 2022
Int. Cl. C07K 14/705 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01)

CPC C07K 14/7051 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61K 40/4261 (2025.01); C07K 14/70521 (2013.01); C07K 16/30 (2013.01); C12N 5/0636 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01)]

12 Claims

1. A membrane bound interleukin 15 (IL-15)-IL-15Rα sushi domain chimeric receptor, comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 27, 28, and 94.